°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

[11¿ù 17ÀÏ] ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö ¾È³»
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2018-09-12
Á¶È¸
3034

´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾öÀÌ ¾Æ·¡¿Í °°ÀÌ °³ÃֵǿÀ´Ï ȸ¿ø ¿©·¯ºÐµéÀÇ ¸¹Àº °ü½É°ú Âü¿© ºÎŹµå¸³´Ï´Ù.

    

= ¾Æ·¡ =

    

ÀϽÃ: 2018³â 11¿ù 17ÀÏ (Åä)

Àå¼Ò: ¼­¿ï´ëÇб³ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦

ÁÖÃÖ: ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸

µî·Ïºñ: ¹«·á

µî·Ï: ÇöÀå ´çÀϵî·Ï!!

ÆòÁ¡: ´ëÇÑÀÇ»çÇùȸ 3Á¡, Ç÷¾×Á¾¾ç³»°úºÐ°úÀü¹®ÀÇ 3Á¡

Time

Program

Speakers

10:00~10:50

Registration

 

10:50~11:00

Opening remarks

À̼® À§¿øÀå

Session I: Toward Detecting High-risk ALL

ÁÂÀå: °¡Å縯ÀÇ´ë À̼®,   Àü³²ÀÇ´ë ¾ç´öȯ

11:00~11:30

NGS-based MRD detection

°æºÏÀÇ´ë ¹®ÁØÈ£

11:30~12:00

Philadelphia Chromosome-like   ALL

°¡Å縯ÀÇ´ë ±è¸í½Å

12:00~12:30

Early T-cell Precursor ALL

¿ï»êÀÇ´ë Á¶¿µ¿í

12:30~14:00

Lunch and Coffee break

Session II: Incorporation of   Immunotherapies into Salvage/Frontline Treatments

ÁÂÀå: °è¸í´ë µµ¿µ·Ï,   ºÎ»ê´ë ½ÅÈ£Áø

14:00~14:30

Anti-CD19 Bispecific T-cell   Engager: Blinatumomab

ÀÎÁ¦ÀÇ´ë ÀÌ¿ø½Ä

14:30~15:00

Anti-CD22 Ab-Drug Conjugate:   Inotuzumab Ozogomicin

°¡Å縯ÀÇ´ë À±ÀçÈ£

15:00~15:30

Updates on CAR T-cell   Therapies

Àü³²ÀÇ´ë Á¤¼ºÈÆ

15:30~

Closing remarks

À̼® À§¿øÀå

´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ À§¿øÀå À̼® / °£»ç ¾ç´öȯ